Table 2.
Heart rate responses in study part 2: delayed administration
| Intravenous placebo | Intravenous atropine | |||
|---|---|---|---|---|
| Response | Oral placebo | Oral fingolimod | Oral placebo | Oral fingolimod |
| Pretitration rate (beats min−1) | 65 ± 10 | 59 ± 11 | 65 ± 10 | 53 ± 8 |
| During titration (1 h): | ||||
| Atropine total dose (mg) | – | – | 1.6 ± 0.5 | 1.9 ± 0.4 |
| Subjects dosed maximally (2 mg) | – | – | 7 | 11 |
| Subjects reaching target rate | – | – | 7 | 0 |
| Maximum rate (beats min−1) | 79 ± 9 | 64 ± 11 | 107 ± 9 | 71 ± 10 |
| Time of maximum rate (min) | 48 (15–60) | 35 (0–60) | 35 (15–55) | 40 (10–60) |
| Rate at 60 min (beats min−1) | 68 ± 13 | 56 ± 9 | 91 ± 8 | 64 ± 8 |
| Full day (24 h): | ||||
| Nadir rate (beats min−1) (0–4 h) | 63 ± 6 | 54 ± 9 | 62 ± 8 | 50 ± 6 |
| AUEC(0–12) (beats min−1 h) | 845 ± 86 | 723 ± 108 | 895 ± 85 | 708 ± 77 |
| AUEC(0,24 h) (beats min−1 h) | 1590 ± 170 | 1363 ± 189 | 1606 ± 161 | 1328 ± 142 |
Values are arithmetic mean ± SD except for tmax which is median (range). AUEC is area under the heart rate effect–time curve. Target heart rate during atropine titration was 110–120 beats min−1.